Passage BIO PASG 深 沪
已收盘 07-02 16:00:00 美东时间
4.68
+0.100
+2.18%
华盛通- 最 高4.73
- 今 开4.64
- 成交量 4.46万股
- 最 低 4.4501
- 昨 收 4.58
- 总市值 1501.26万
- 52周最高 20.00
- 市盈率 静 --
- 换手率 1.39%
- 52周最低 3.29
- 委 比 -96.70%
- 总股本 320.78万
- 历史最高 764.60
- 量 比 0.17
- 振 幅 6.11%
- 历史最低 3.29
- 每 手 1
- 风险率 2.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | 中驰车福涨95.61%，Eco Wave Power Global AB Sponsored ADR涨29.71%
Elme Communities涨-26.24%；宝视来涨-18.24%；Passage BIO涨-17.52%
06-25 08:05
9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines (NASDAQ:GRML) stock moved upwards by 7.18% to $0.24. The company's market cap stands at $34.7 million. Lunai...
06-25 05:05
Passage Bio, Remix Therapeutics Sign All-Stock Business Combination Agreement; Combined Entity To Operate Under Remix Therapeutics, RMTX Ticker On Nasdaq
Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix"), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that they have entered into a definitive merge...
06-25 04:07
Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio and Remix Therapeutics have agreed to merge in an all-stock transaction, with the combined company operating as Remix Therapeutics. The merger is supported by a $100 million private placement financing, which will fund operations into 2028. Remix’s lead program, REM-422, an mRNA degrader targeting MYB, is in Phase 1/2 trials for cancers like ACC and AML. The transaction is expected to close in Q4 2026, with the combined company led by...
06-24 20:05
Passage Bio Ends Key Collaborations and Office Lease
Passage Bio ( ($PASG) ) has provided an announcement. On May 21, 2026, Passage ...
05-28 05:31
Passage Bio Terminates Research, Collaboration And License Agreement With Gemma Bio Therapeutics
- Sec Filing
05-28 04:51
Passage Bio Shareholders Approve Directors and Executive Pay
Passage Bio ( ($PASG) ) has provided an update. On May 19, 2026, Passage Bio, I...
05-26 19:44
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
TD Cowen Downgrades Passage Bio to Hold
TD Cowen analyst Brendan Smith downgrades Passage Bio (NASDAQ:PASG) from Buy to Hold.
04-22 00:21
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis April 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CNX Resources, P&G and Prologis on Tuesday. HIGHLIGHTS * CNX Resources Corp CNX.N : Gerdes Energy Research raise
04-21 16:08
